Metastatic Breast Cancer
There are approximately 3.5 million women living in the US with a history of breast cancer.
Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later in the disease course (distant recurrence), represent the majority of MBC cases and constitute the most advanced form of breast cancer. By 2020 there will be 168,292 women living with MBC in the US.
The majority of the MBC population (3 out of 4) were initially diagnosed with non-metastatic cancer but progress to distant disease. While five-year relative survival is 89.7% for all female breast cancer patients, the rate for MBC patients drops precipitously to 27%. Additionally, 20% of breast cancer deaths in a given year originate from women diagnosed with de novo MBC, whereas 80% are deaths from women diagnosed with earlier stage breast cancer who progressed to recurrent MBC.
These results demonstrate the strong unmet need for new treatments, and AX09 is designed to address this need by prolonging survival in the MBC patient population.
Colorectal Cancer (CRC) is the second leading cause of cancer related deaths in the US for both men and women combined.
Non-small Cell Lung Cancer
An estimated 234,000 adults in the US will be diagnosed with lung cancer.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for 80-85% of all lung cancer diagnoses. Lung Cancer is the second most common and the leading cancer death for men and women. It is estimated that 154,000 deaths from this disease will occur each year.
It has also been reported that there is overexpression of xCT in NSCLC and the expression of xCT was correlated with advanced stage and predicted a worse 5-year survival.
This demonstrates that xCT is also a viable therapeutic target for the treatment of NSCLC, and AgilVax’s AX09 represents the ideal candidate.